Home
Conditions
Refractory Follicular Lymphoma

Clinical trial condition

Refractory Follicular Lymphoma

Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

35 public trials 6 recruiting studies

Refine in advanced search Browse all conditions

Refractory Follicular Lymphoma trial results

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

NCT06948786

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +59 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

NCT05848765

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: NHS Grampian Aberdeen, United Kingdom

Belfast Health & Social Care Trust Belfast, United Kingdom

University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom

Blackpool Teaching Hospitals NHS Foundation Trust Blackpool, United Kingdom

View all 25 locations

View Trial Details

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887

Conditions: B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
Locations: Mayo Clinic in Florida Jacksonville, Florida, United States

View Trial Details

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, not recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Southern Cancer Center Mobile, Alabama, United States

Arizona Oncology Associates - Tuscon-Rusadill Road Tucson, Arizona, United States

TOI - Clinical Research Cerritos, California, United States

UCSF Fresno Clovis, California, United States

View all 204 locations

View Trial Details

Active, not recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations: Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

Alaska Oncology and Hematology LLC Anchorage, Alaska, United States

Alaska Women's Cancer Care Anchorage, Alaska, United States

Anchorage Oncology Centre Anchorage, Alaska, United States

View all 429 locations

View Trial Details

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Active, not recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions: Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations: City of Hope Medical Center Duarte, California, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

University of Nebraska Medical Center Omaha, Nebraska, United States

View Trial Details

Refractory Follicular Lymphoma

Refractory Follicular Lymphoma trial results

Related conditions